SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing intense downward pressure and high volatility as investors aggressively sell off precious metals, defying the traditional 'safe haven' narrative during geopolitical conflict. The community is actively debating whether this is a temporary liquidity-driven shakeout caused by margin calls and institutional rebalancing, or a fundamental shift in sentiment as the dollar strengthens and investors pivot toward high-yield alternatives.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors gear up for the upcoming earnings report, with heated community debate surrounding CEO compensation proposals and persistent speculation about potential large-scale acquisitions. The conversation remains heavily focused on alleged market manipulation and short-interest dynamics, keeping market participants on high alert for volatility as the earnings date approaches.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is facing extreme volatility as investors react to a federal indictment involving a company co-founder and employees in an alleged scheme to divert restricted technology to China. While some community members view the sharp sell-off as a temporary reaction to isolated bad actors, others are aggressively bearish, citing concerns over systemic management failure, potential loss of partner trust, and the risk of further regulatory intervention.

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings is seeing significant volatility as retail investors debate the company's unique community-owned, 'ShareBack' business model following its direct listing. While some traders are aggressively playing the stock for short-term squeezes and comparing it to previous micro-cap runners, others are skeptical of its valuation and lack of revenue, leading to intense community discussion over whether it represents a transformative platform or a potential trap.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing heightened trading activity as the market reacts to mixed earnings reports and anticipation surrounding the upcoming March 12 investor event. The community is sharply divided, with bulls pointing to the potential of a mid-size vehicle platform to drive long-term growth, while bears remain focused on persistent cash burn, dilution risks, and the company's long path toward profitability.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense market volatility as investors weigh the potential for a global energy supply shock against expectations of a tactical rebound in tech stocks. Market sentiment remains highly polarized, with traders debating whether escalating geopolitical tensions in the Middle East have been adequately priced in or if a deeper market correction is imminent.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently trending as investors capitalize on the company's major spectrum license sales to SpaceX and AT&T, which are expected to leave the firm with a massive net cash position and no debt. Community sentiment remains highly bullish, with many traders framing the stock as an undervalued proxy for indirect SpaceX equity exposure, while keeping a close eye on upcoming regulatory approvals for these landmark deals.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart Holdings is trending as investors weigh a major strategic pivot to become a federally insured national bank against ongoing volatility and concerns regarding credit market exposure. While some market participants anticipate a potential short squeeze due to high short interest, others remain cautious as the stock continues to navigate sector-wide pressure and mixed sentiment from retail traders.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) is facing extreme selling pressure as investors aggressively unwind overcrowded positions amid broader market volatility and a surging US dollar. The community remains deeply divided, with some traders viewing the sharp pullback as a necessary correction to shake out weak hands before a potential resumption of the long-term uptrend, while others caution that rising energy costs and economic uncertainty could signal a deeper, more sustained reversal for the sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure and heightened volatility as traders weigh concerns over the company's aggressive pivot toward physical AI and chip manufacturing against broader market anxiety regarding geopolitical tensions. Investors remain deeply divided, with many debating the feasibility of the newly announced chip infrastructure while expressing frustration over the stock's recent multi-month decline and the influence of leadership sentiment on its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat Ratings reports. One...

Promising Biotech Stocks To Keep An Eye On - March 21st

Danaher, Vertex Pharmaceuticals, Moderna, United Therapeutics, ImmunityBio, argenex, and Medpace are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

ImmunityBio (NASDAQ:IBRX) Stock Price Down 4%  - Should You Sell?

ImmunityBio (NASDAQ:IBRX) Trading Down 4% - Time to Sell...

ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of unusually large options trading on Friday. Investors acquired 51,571 call options on the stock. This is an increase of 50...

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA in BCG-Unresponsive NMIBC with CIS Papillary Tumors

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the Peoples Republic of China has granted...

<ul class="summary-bullets"><li>A record $5.7 trillion “triple witching” options expiry threatens to inject fresh swings into an already fragile market.</li><li>Markets remain on edge as escalating Middle East tensions fuel oil volatility.</li><li>SMCI stock tanks 20% in early pre-market trade on alleged Nvidia chip diversion to China.&nbsp;</li></ul>U.S. stock futures took a breather early Friday with investors parsing the latest developments in the Middle East. However, fresh Israeli strikes on Iran and risks around the Strait of Hormuz are keeping oil volatility in action.Traders will also be&nbsp; focusing on a historic options expiration. They are&nbsp; bracing for a staggering $5.7 trillion in notional options to expire today, which is reportedly the largest March expiry in Citigroup data going back to 1996.&nbsp; As of 4:00 a.m. ET on Friday, Dow futures rose 0.2%, S&amp;P futures gained 0.1%, the Nasdaq futures were flat with a positive bias, and Russell 2000 futures were up 0.3%.Caution prevails among the traders. Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘extremely bearish, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bearish’ amid high trading volume.&nbsp;Trending Stocks To Watch Super Micro Computer (SMCI):&nbsp;The stock is on retail radar this morning after U.S. prosecutors charged three individuals, including a co-founder and a board member, in a scheme to smuggle Nvidia (NVDA) chips to China. Both companies have stressed on compliance in their statements.&nbsp;Nvidia (NVDA) &amp; Amazon (AMZN):&nbsp;Despite the SMCI scandal, Nvidia remains in focus following reports it will sell 1 million chips to Amazon by the end of 2027 as part of a massive cloud infrastructure deal. Amazon also boosted its logistics wing by acquiring the autonomous robotics startup Rivr.Meta (META): The company reportedly reversed its decision to shut down&nbsp;Horizon Worlds for Quest VR headsets, citing fan feedback.Tech stocks also remain in the spotlight on reports that the White House is expected to release a&nbsp;national AI regulatory framework in the coming days.&nbsp;Tesla (TSLA):&nbsp;The EV giant is back in focus as it doubles down on its solar and energy ambitions with a $2.9 billion China-linked expansion, while also nearing a potential rollout of its Full Self-Driving (FSD) software in Europe.FedEx (FDX): The stock is garnering retail attention following a Q3 earnings beat and a raised FY26 outlook. Analysts at Wells Fargo and JPMorgan raised price targets to $430–$432.&nbsp;Investors are shifting focus to&nbsp;rare earth stocks (MP, UAMY, USAR) following a landmark joint action plan between the U.S. and Japan. The two nations announced a $73 billion energy and minerals initiative, including the development of deep-sea rare earth muds near Minamitori Island.&nbsp;Azitra Inc. (AZTR):&nbsp;The stock is seeing strong pre-market action following the pricing of a $31.4 million private placement financing.ImmunityBio, Inc. (IBRX): Its cancer therapy Anktiva appeared on Macau’s latest drug list. Also, the founder has flagged early immune activation data from an Anktiva study.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Firefly Aerospace (FLY), AppLovin Corp (APP), and Qualcom (QCOM).&nbsp;On earnings radar, watch out for quarterly reports from Milestone Scientific (MIST), XPeng (XPEV), and Zegna (ZGN) before the bell today.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Take A Breather Ahead Of Massive Options Expiry: Why SMCI, NVDA, TSLA, UAMY, IBRX Are Keeping Traders Engaged Today

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ. 

Equity

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ. 


<ul class="summary-bullets"><li>Executive chairman Patrick Soon-Shiong highlighted early immune activation data from an Anktiva study.</li><li>Anktiva was also added to Macau’s drug list and included in updated NCCN guidelines for papillary bladder cancer.</li><li>ImmunityBio has resubmitted its FDA application for label expansion, while advancing lung cancer trials and expanding global approvals.</li></ul>Shares of ImmunityBio, Inc. (IBRX) posted modest gains in premarket trading on Friday after executive chairman and founder Patrick Soon-Shiong flagged early immune data from an Anktiva study, adding to momentum from recent regulatory and global developments.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained over 5% this week, snapping a two-week losing streak that had erased nearly 15% of its value.<h2 class="st-heading-2">Early Anktiva Data Shows Immune Activation</h2>Soon-Shiong said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2034892413802545271">post on X</a> that initial analysis from the first 20 subjects showed immune activation with Anktiva in combination with the company’s adenovirus-based cancer vaccine. The trial has enrolled 138 patients randomized to the combination or placebo. Data generated by the U.S. National Cancer Institute team showed confirmation of Anktiva’s immune-stimulating effect on absolute lymphocyte count.He added that baseline lymphocyte levels decline with age but appear to increase with Anktiva, citing research linking low levels to reduced lifespan. Soon-Shion also added that cancer vaccine trials are ongoing.<h2 class="st-heading-2">Anktiva Gains Macau Listing, NCCN Backing</h2>The update comes as Anktiva was added to Macau’s latest&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-snap-losing-streak-anktiva-macau-drug-list/cZ3XLBrRIhU">approved drug</a> list as a bladder cancer treatment. The inclusion places it alongside therapies from Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Gilead Sciences and Moderna.In the U.S., the National Comprehensive Cancer Network (NCCN) added Anktiva with BCG as an “other recommended” option for papillary bladder cancer that no longer responds to BCG, expanding its use beyond carcinoma in situ.<h2 class="st-heading-2">Anktiva Pipeline Expands With Strong Data</h2>ImmunityBio has resubmitted its application to expand Anktiva’s label to papillary bladder cancer after a prior refusal-to-file. In the Phase 2/3 Quilt 3.032 study, 58.2% of patients remained cancer-free at 12 months, while more than 80% avoided bladder removal surgery over three years, according to the company.The therapy is also being studied in lung cancer, with two pivotal trials underway, and has received authorizations in the U.K., Europe and Saudi Arabia.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX slid to ‘bearish’ from the ‘extremely bullish’ zone over the past three months amid over a 300% surge in message volumes over the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_ba9f17d55e.webp" alt="ibrx ss.png" width="963" height="143"><figcaption>IBRX sentiment and message volume as of March 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/ActionCuresFear/message/648063131">said</a>, The market prices a bladder cancer drug. NCI just showed data proving it works on immune decline in people without cancer.”<stembedurl>https://stocktwits.com/ActionCuresFear/message/648063131</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Adi121/message/648063344">said</a>, “Anktiva is heading towards becoming universal cancer vaccine! Lynch syndrome is the proof of concept!”<stembedurl>https://stocktwits.com/Adi121/message/648063344</stembedurl>IBRX stock has more than tripled over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dr. Patrick Soon-Shiong arrives at Trump National Golf Club Bedminster in Bedminster Township, N.J. on Saturday, Nov. 19, 2016. (Photo by Jabin Botsford/The Washington Post via Getty Images)

IBRX Stock Rises Premarket As Founder Flags Early Anktiva Immune Data — Macau Nod Fuels Bull Case

 Early trial data showed immune activation in initial patients, with Anktiva boosting lymphocyte levels.

<ul class="summary-bullets"><li>The therapy also gained momentum in the U.S. after NCCN added it as a treatment option for papillary bladder cancer patients unresponsive to BCG.</li><li>ImmunityBio has resubmitted its FDA application to expand Anktiva’s use, backed by clinical data showing strong cancer-free and bladder preservation rates.</li><li>The company is advancing Anktiva globally, with lung cancer trials underway and recent approvals in markets including Saudi Arabia.</li></ul>Shares of ImmunityBio, Inc. (IBRX) are set to snap a two-week losing streak after its cancer therapy Anktiva appeared on Macau’s latest drug list, adding to fresh momentum from a U.S. guideline expansion.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained over 5% this week, snapping a two-week losing streak that had erased nearly 15% of its value.<h2 class="st-heading-2">Anktiva Added To Macau Approved List</h2>Anktiva, which is available under the generic name Nogapendekin alfa, is an immunotherapy that helps activate the body’s immune system to better fight cancer. It is approved in the U.S. for use with standard BCG treatment in patients with a type of bladder cancer that no longer responds to BCG, including those with or without certain tumor growths.The Macau filing, with data as of March, lists Anktiva as a bladder cancer treatment, identifying Nogapendekin alfa as its active ingredient and noting it is given as an injection for bladder cancer. The list also includes therapies approved by regulators such as the U.S. Food and Drug Administration (FDA), China’s National Medical Products Administration (NMPA), and the European Medicines Agency (EMA).Anktiva’s inclusion places it alongside a roster of globally approved therapies from major drugmakers, including Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Janssen, Gilead Sciences, and Moderna, positioning it among established treatments across oncology and specialty care.<h2 class="st-heading-2">NCCN Expansion Adds To Momentum</h2>The Macau development comes in the same week that Anktiva was added to updated U.S. treatment guidelines. The National Comprehensive Cancer Network (NCCN) added Anktiva, used with BCG, as an “other recommended” option for patients with papillary bladder cancer that no longer responds to BCG and has not spread into muscle tissue.Earlier versions of the guidelines had included the therapy only for carcinoma in situ. The update expands the potential patient population under clinical guidance, even as the indication is not yet formally approved by the FDA.<h2 class="st-heading-2">Anktiva Seeks Label Expansion</h2>ImmunityBio is seeking to expand Anktiva’s label to include papillary bladder cancer and has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-declines-immunitybio-resubmits-anktiva-application-to-fda/cZdVj9URIIL">resubmitted</a> its supplemental biologics license application to the FDA after previously receiving a refusal-to-file letter. The filing includes additional data requested by the agency, including updated efficacy results and long-term follow-up.Clinical data from the Phase 2/3 Quilt 3.032 study showed that 58.2% of patients remained cancer-free at 12 months, while more than 80% avoided bladder removal surgery over a three-year follow-up period, according to the company.<h2 class="st-heading-2">Global Push For Anktiva Grows</h2>Beyond bladder cancer, ImmunityBio is advancing Anktiva in lung cancer, with two pivotal trials underway in first-line and second-line non-small cell lung cancer. The company said multiple countries have expressed interest in the program as it explores broader regulatory pathways.The therapy has already received authorizations in the U.K., Europe and Saudi Arabia. In January, Saudi regulators granted approvals covering both bladder cancer and metastatic non-small cell lung cancer, including use in combination with checkpoint inhibitors.ImmunityBio said product shipments are ready to begin for a Saudi launch of Anktiva for bladder cancer, following regulatory approvals, and that it has partnered with regional distributors to expand access across the Middle East and North Africa.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX slid to ‘bearish’ from the ‘extremely bullish’ zone over the past three months amid over a 300% surge in message volumes over the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_ba9f17d55e.webp" alt="ibrx ss.png" width="963" height="143"><figcaption>IBRX sentiment and message volume as of March 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648013012">said</a>, “Macau - China. I’d say that’s kinda global. And unstoppable.”<stembedurl>https://stocktwits.com/cyberInvest/message/648013012</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648034961">said</a>, “with NMPA - Macau - China approval apparent, FDA needs to get with it. This level of disfunction is a national embarrassment. China approves before US for a US company??? This is like a Saturday Night Live skit.”<stembedurl>https://stocktwits.com/cyberInvest/message/648034961</stembedurl>IBRX stock has more than tripled over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List 

IBRX Stock - Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

ImmunityBio (NASDAQ:IBRX) Shares Up 3%  - Should You Buy?

ImmunityBio (NASDAQ:IBRX) Stock Price Up 3% - Here's Why...

ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.3% - Here's Why

ImmunityBio (NASDAQ:IBRX) Shares Up 4.3% - Should You Buy...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

With 132M shares short and 100% utilization, traders are betting on a massive, rapid breakout as trapped short sellers look for an exit.

Strategic partnership reports for local manufacturing in Riyadh signal significant international validation and revenue potential in the MENA region.

Investors are closely watching new federal cancer vaccine initiatives and potential federal funding that could drastically accelerate treatment adoption.

Recent regulatory approvals in Macau provide a critical beachhead for expansion into broader Asian markets and China.

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBRX News

IBRXImmunityBio Inc